Patient characteristics
. | Patients, n = 60 . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| . | PET−, n = 30 . | . | PET+, n = 30 . | . | |||
| Clinical outcome . | CR, n = 27 . | Relapse, n = 3 . | CR, n = 4 . | Relapse, n = 26 . | |||
| Age, y, median (range) | 38 (15-65) | 32 (17-47) | 36 (35-56) | 34.5 (12-62) | |||
| Sex, M/F | 16/11 | 2/1 | 3/1 | 16/10 | |||
| Status | |||||||
| Primary refractory disease | 14 | 1 | 2 | 11 | |||
| First relapse | 9 | 1 | 1 | 11 | |||
| Second relapse | 4 | 1 | 1 | 4 | |||
| Stage at progression or relapse | |||||||
| I | 3 | 0 | 0 | 2 | |||
| II | 12 | 2 | 3 | 12 | |||
| III | 3 | 0 | 0 | 6 | |||
| IV | 9 | 1 | 1 | 6 | |||
| B symptoms at progression, yes/no | 12/15 | 1/2 | 1/3 | 9/17 | |||
| Histology | |||||||
| HD, nodular sclerosis | 7 | 0 | 2 | 7 | |||
| HD, mixed cellularity | 2 | 0 | 0 | 0 | |||
| HD, lymphocyte predominant | 0 | 1 | 0 | 0 | |||
| NHL, diffuse large B-cell lymphoma | 11 | 1 | 1 | 9 | |||
| NHL, anaplastic large B-cell lymphoma | 3 | 1 | 1 | 7 | |||
| NHL, mantle-cell lymphoma | 4 | 0 | 0 | 3 | |||
| Prognostic score | |||||||
| HD, score 0 | 1 | 0 | 1 | 4 | |||
| HD, score 1 | 3 | 0 | 1 | 2 | |||
| HD, score 2 | 4 | 1 | 0 | 1 | |||
| HD, score 3 | 0 | 0 | 0 | 0 | |||
| HD, score 4 | 1 | 0 | 0 | 0 | |||
| NHL, low | 10 | 2 | 1 | 13 | |||
| NHL, low-intermediate | 4 | 0 | 1 | 4 | |||
| NHL, high-intermediate | 2 | 0 | 0 | 2 | |||
| NHL, high | 2 | 0 | 0 | 0 | |||
| Frontline therapy | |||||||
| CHOP | 13 | 1 | 2 | 17 | |||
| MOPP-ABV | 6 | 1 | 1 | 4 | |||
| CHVmP-BV | 4 | 1 | 0 | 3 | |||
| Stanford | 4 | 0 | 1 | 2 | |||
| Salvage therapy | |||||||
| VIM-DHAP | 23 | 2 | 1 | 18 | |||
| dexa-BEAM | 4 | 1 | 3 | 8 | |||
| Transplantation | |||||||
| Autologous | 25 | 3 | 4 | 22 | |||
| Allogeneic | 2 | 0 | 0 | 4 | |||
. | Patients, n = 60 . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| . | PET−, n = 30 . | . | PET+, n = 30 . | . | |||
| Clinical outcome . | CR, n = 27 . | Relapse, n = 3 . | CR, n = 4 . | Relapse, n = 26 . | |||
| Age, y, median (range) | 38 (15-65) | 32 (17-47) | 36 (35-56) | 34.5 (12-62) | |||
| Sex, M/F | 16/11 | 2/1 | 3/1 | 16/10 | |||
| Status | |||||||
| Primary refractory disease | 14 | 1 | 2 | 11 | |||
| First relapse | 9 | 1 | 1 | 11 | |||
| Second relapse | 4 | 1 | 1 | 4 | |||
| Stage at progression or relapse | |||||||
| I | 3 | 0 | 0 | 2 | |||
| II | 12 | 2 | 3 | 12 | |||
| III | 3 | 0 | 0 | 6 | |||
| IV | 9 | 1 | 1 | 6 | |||
| B symptoms at progression, yes/no | 12/15 | 1/2 | 1/3 | 9/17 | |||
| Histology | |||||||
| HD, nodular sclerosis | 7 | 0 | 2 | 7 | |||
| HD, mixed cellularity | 2 | 0 | 0 | 0 | |||
| HD, lymphocyte predominant | 0 | 1 | 0 | 0 | |||
| NHL, diffuse large B-cell lymphoma | 11 | 1 | 1 | 9 | |||
| NHL, anaplastic large B-cell lymphoma | 3 | 1 | 1 | 7 | |||
| NHL, mantle-cell lymphoma | 4 | 0 | 0 | 3 | |||
| Prognostic score | |||||||
| HD, score 0 | 1 | 0 | 1 | 4 | |||
| HD, score 1 | 3 | 0 | 1 | 2 | |||
| HD, score 2 | 4 | 1 | 0 | 1 | |||
| HD, score 3 | 0 | 0 | 0 | 0 | |||
| HD, score 4 | 1 | 0 | 0 | 0 | |||
| NHL, low | 10 | 2 | 1 | 13 | |||
| NHL, low-intermediate | 4 | 0 | 1 | 4 | |||
| NHL, high-intermediate | 2 | 0 | 0 | 2 | |||
| NHL, high | 2 | 0 | 0 | 0 | |||
| Frontline therapy | |||||||
| CHOP | 13 | 1 | 2 | 17 | |||
| MOPP-ABV | 6 | 1 | 1 | 4 | |||
| CHVmP-BV | 4 | 1 | 0 | 3 | |||
| Stanford | 4 | 0 | 1 | 2 | |||
| Salvage therapy | |||||||
| VIM-DHAP | 23 | 2 | 1 | 18 | |||
| dexa-BEAM | 4 | 1 | 3 | 8 | |||
| Transplantation | |||||||
| Autologous | 25 | 3 | 4 | 22 | |||
| Allogeneic | 2 | 0 | 0 | 4 | |||